Erasca, Inc. (ERAS)
14.98
-0.14
(-0.93%)
USD |
NASDAQ |
Oct 29, 16:00
15.00
+0.02
(+0.13%)
After-Hours: 20:00
Erasca Enterprise Value : 4.458B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 4.458B |
| October 28, 2026 | 4.502B |
| October 27, 2026 | 4.533B |
| October 26, 2026 | 4.461B |
| October 23, 2026 | 4.274B |
| October 22, 2026 | 4.164B |
| October 21, 2026 | 4.305B |
| October 20, 2026 | 4.346B |
| October 19, 2026 | 4.033B |
| October 16, 2026 | 3.961B |
| October 15, 2026 | 4.424B |
| October 14, 2026 | 4.371B |
| October 13, 2026 | 4.396B |
| October 12, 2026 | 4.608B |
| October 09, 2026 | 4.786B |
| October 08, 2026 | 4.608B |
| October 07, 2026 | 4.189B |
| October 06, 2026 | 4.246B |
| October 05, 2026 | 4.377B |
| October 02, 2026 | 4.383B |
| October 01, 2026 | 4.333B |
| September 30, 2026 | 4.358B |
| September 29, 2026 | 4.217B |
| September 28, 2026 | 4.192B |
| September 25, 2026 | 4.230B |
| Date | Value |
|---|---|
| September 24, 2026 | 4.314B |
| September 23, 2026 | 4.135B |
| September 22, 2026 | 4.636B |
| September 21, 2026 | 4.477B |
| September 18, 2026 | 4.392B |
| September 17, 2026 | 4.571B |
| September 16, 2026 | 4.577B |
| September 15, 2026 | 4.855B |
| September 14, 2026 | 4.827B |
| September 11, 2026 | 4.739B |
| September 10, 2026 | 4.786B |
| September 09, 2026 | 4.683B |
| September 08, 2026 | 4.864B |
| September 04, 2026 | 4.836B |
| September 03, 2026 | 4.858B |
| September 02, 2026 | 4.893B |
| September 01, 2026 | 5.014B |
| August 31, 2026 | 5.364B |
| August 28, 2026 | 5.411B |
| August 27, 2026 | 5.868B |
| August 26, 2026 | 5.761B |
| August 25, 2026 | 5.327B |
| August 24, 2026 | 5.277B |
| August 21, 2026 | 5.286B |
| August 20, 2026 | 5.114B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.312B |
| Twist Bioscience Corp. | 10.80B |
| Immunome, Inc. | 1.556B |
| Oncolytics Biotech, Inc. | 49.64M |
| Sangamo Therapeutics, Inc. | 41.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.08M |
| Total Expenses (Quarterly) | 44.08M |
| EPS Diluted (Quarterly) | -0.1416 |
| Earnings Yield | -6.37% |
| Normalized Earnings Yield | -4.037 |